Resultados da busca - Alexander Astrakhan
- Mostrando 1 - 7 resultados de 7
-
1
B cell–specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia por Hannah M. Kerns, Byoung Y. Ryu, Brigid Stirling, Blythe Sather, Alexander Astrakhan, Stéphanie Humblet‐Baron, Denny Liggitt, David J. Rawlings
Publicado em 2010Artigo -
2
Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome por Alexander Astrakhan, Blythe Sather, Byoung Y. Ryu, Socheath Khim, Swati Singh, Stéphanie Humblet‐Baron, Hans D. Ochs, Carol H. Miao, David J. Rawlings
Publicado em 2012Artigo -
3
megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering por Sandrine Boissel, Jordan Jarjour, Alexander Astrakhan, Andrew Adey, Agnès Gouble, Philippe Duchâteau, Jay Shendure, Barry Stoddard, Michael T. Certo, David Baker, Andrew M. Scharenberg
Publicado em 2013Artigo -
4
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization por Wai-Hang Leung, Joel Gay, Unja Martin, Tracy E. Garrett, Holly M. Horton, Michael T. Certo, Bruce R. Blazar, Richard A. Morgan, Philip D. Gregory, Jordan Jarjour, Alexander Astrakhan
Publicado em 2019Artigo -
5
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells por Malika Hale, Baeckseung Lee, Yuchi Honaker, Wai‐Hang Leung, Alexandra E. Grier, Holly M. Jacobs, Karen Sommer, Jaya Sahni, Shaun W. Jackson, Andrew M. Scharenberg, Alexander Astrakhan, David J. Rawlings
Publicado em 2017Artigo -
6
Efficient modification of <i>CCR5</i> in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template por Blythe Sather, Guillermo S. Romano Ibarra, Karen Sommer, Gabrielle Curinga, Malika Hale, Iram Khan, Swati Singh, Yumei Song, Kamila Gwiazda, Jaya Sahni, Jordan Jarjour, Alexander Astrakhan, Thor A. Wagner, Andrew M. Scharenberg, David J. Rawlings
Publicado em 2015Artigo -
7
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing por Jacob Appelbaum, April E. Price, Kaori Oda, Joy Zhang, Wai‐Hang Leung, Giacomo Tampella, Dong Xia, Pauline Pl So, Sarah K. Hilton, Claudya Evandy, Semanti Sarkar, Unja Martin, Anne-Rachel Krostag, Marissa Leonardi, Daniel E. Zak, Rachael Logan, Paula Lewis, Secil Franke-Welch, Njabulo Ngwenyama, Michael Fitzgerald, Niklas Tulberg, Stephanie D. Rawlings‐Rhea, Rebecca Gardner, Kyle M. L. Jones, Angelica Sanabria, William Crago, John C. Timmer, Andrew Hollands, Brendan P. Eckelman, Sanela Bilic, Jim Woodworth, Adam J. Lamble, Philip D. Gregory, Jordan Jarjour, Mark Pogson, Joshua A. Gustafson, Alexander Astrakhan, Michael C. Jensen
Publicado em 2024Artigo
Ferramentas de busca:
Assuntos relacionados
Biology
Cell biology
Gene
Genetics
Computational biology
Immune system
Immunology
Internal medicine
Medicine
Antibody
B cell
Biochemistry
Biotechnology
Cancer research
Chemistry
Chimeric antigen receptor
Effector
Genetic enhancement
Haematopoiesis
Immunotherapy
In vivo
Nuclease
Stem cell
T cell
Transplantation
Actin cytoskeleton
Antigen
Artificial intelligence
Biophysics
Bruton's tyrosine kinase